In the past week, ZVSA stock has gone up by 42.59%, with a monthly gain of 49.64% and a quarterly surge of 56.38%. The volatility ratio for the week is 6.43%, and the volatility levels for the last 30 days are 10.32% for ZyVersa Therapeutics Inc The simple moving average for the last 20 days is 40.55% for ZVSA stock, with a simple moving average of -17.25% for the last 200 days.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
Moreover, the 36-month beta value for ZVSA is 0.81. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ZVSA is 4.86M and currently, short sellers hold a 3.89% of that float. On July 08, 2025, ZVSA’s average trading volume was 4.09M shares.
ZVSA stock’s latest price update
ZyVersa Therapeutics Inc (NASDAQ: ZVSA) has seen a rise in its stock price by 46.22% in relation to its previous close of $0.66. However, the company has experienced a 42.59% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-08 that ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease. Despite being treated with standard-of-care renal drug therapy (ACEi, SGLT2, statin, and ezetimibe), the patient authorized by FDA to receive VAR 200 is showing continued kidney disease progression.
ZVSA Trading at 53.15% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.67% of loss for the given period.
Volatility was left at 10.32%, however, over the last 30 days, the volatility rate increased by 6.43%, as shares surge +28.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.47% upper at present.
During the last 5 trading sessions, ZVSA rose by +24.06%, which changed the moving average for the period of 200-days by -65.99% in comparison to the 20-day moving average, which settled at $0.6807. In addition, ZyVersa Therapeutics Inc saw -73.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of ZyVersa Therapeutics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for ZVSA
The total capital return value is set at -0.24%. Equity return is now at value -91.39%, with -41.48% for asset returns.
Currently, EBITDA for the company is -9.14 billion with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.18.
Conclusion
To wrap up, the performance of ZyVersa Therapeutics Inc (ZVSA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
